Sort   by:  
 Page size 
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (B.animalis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1264 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis (FIA-MS) (C.saccharolyticum;E.coli;L.plantarum;L.lactis;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1791 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (L.saccharolytica;Standards assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS2885 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: duloxetine accumulation at different concentrations (L.saccharolytica;E.coli assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1319 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (E.coli;C.saccharolyticum;S.salivarius;E.rectale;L.plantarum;L.lactis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1627 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1792 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis for resting cells (B.uniformis;C.saccharolyticum assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1757 | MetaboLights
TranscriptomicsDifferential regulation of microRNAs in skeletal muscle from monozygotic twins discordant for type 2 diabetes
Analysis of microRNA expression in vastus lateralis muscle biopsies from 11 genetically identical twin pairs discordant for type 2 diabetes. This eliminates the influence of genotype and leads to the identification of microRNAs that are exclusively influenced by environmental (non-genetic) factors. ...
ORGANISM(S): Homo sapiens 
2014-11-19 | E-GEOD-38835 | biostudies-arrayexpress
UnknownEffects of Nutritional Interventions in Older Adults with Malnutrition or at Risk of Malnutrition on Muscle Strength and Mortality: Results of Pooled Analyses of Individual Participant Data from Nine RCTs.
Not available
S-EPMC10181186 | biostudies-literature
ProteomicsOverexpression of griseusins in Streptomyces sp. CA-256286
Employing multi-omics methods for overexpression of griseusins in Streptomyces sp. CA-25628. This set of data proves that the introduction of the SARPs regulator activates the production of griseusins ( [M+H]+= 749.2589, 586.2288, 796.2771), the inactivation of the griseusin expression using CRISPR-...
ORGANISM(S): Streptomyces Sp. Ca-256286 Streptomyces Albus J1074 (ncbitaxon:457425) 
2021-05-21 | MSV000087475 | MassIVE
Sort   by:  
 Page size